David S Schrump
National Cancer Institute (NCI) · NCI - Surgery Branch
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
25
all conditions, ClinicalTrials.gov
NIH grants tied to them
10
NIH RePORTER
Trial papers
9
PubMed author-name match
Trials
Studies that name David S Schrump as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:02 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06694454 · Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI) · suspended · Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma · principal investigator
- Ph2NCT06654050 · Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage MesotheliomaNational Cancer Institute (NCI) · withdrawn · Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma · principal investigator
- Ph2NCT05960773 · Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaNational Cancer Institute (NCI) · recruiting · Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma · principal investigator
- Ph1/Ph2NCT05898828 · Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerNational Cancer Institute (NCI) · withdrawn · Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm · principal investigator
- Ph1/Ph2NCT05642195 · Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerNational Cancer Institute (NCI) · suspended · Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph1NCT05375825 · Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing MesothelinNational Cancer Institute (NCI) · withdrawn · Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant · principal investigator
- Ph1/Ph2NCT04648826 · Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesNational Cancer Institute (NCI) · withdrawn · Sarcomas, Melanomas, Germ Cell Tumors · principal investigator
- N/ANCT04431024 · Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition SyndromeNational Cancer Institute (NCI) · recruiting · Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS) · principal investigator
- Ph1/Ph2NCT03233724 · Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasNational Cancer Institute (NCI) · terminated · Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT02859415 · Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNational Cancer Institute (NCI) · terminated · Esophageal Neoplasms, Lung Neoplasms, Mesothelioma · principal investigator
- Ph1NCT02839694 · Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary MetastasectomyNational Cancer Institute (NCI) · withdrawn · Neoplasm Metastasis, Sarcoma, Neoplasms, Germ Cell and Embryonal · principal investigator
- Ph1/Ph2NCT02054104 · Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or MediastinumNational Cancer Institute (NCI) · terminated · Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura · principal investigator
- Ph2NCT01624090 · Mithramycin for Lung, Esophagus, and Other Chest CancersNational Cancer Institute (NCI) · terminated · Lung Cancer, Esophageal Cancer, Mesothelioma · principal investigator
- Ph1NCT01341496 · Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalNational Cancer Institute (NCI) · terminated · Sarcoma, Melanoma, Epithelial Malignancies · principal investigator
- Ph1NCT01313429 · Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumNational Cancer Institute (NCI) · terminated · Sarcoma, Melanoma, Epithelial Malignancies · principal investigator
- Ph1NCT01258868 · Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasNational Cancer Institute (NCI) · terminated · Mesolthelioma, Esophageal Cancer, Lung Cancer · principal investigator
- Ph2NCT01160445 · Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Metastatic Renal Cancer · principal investigator
- Ph1NCT01143545 · Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasNational Cancer Institute (NCI) · terminated · Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma · principal investigator
- Ph2NCT00020202 · FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerNational Cancer Institute (NCI) · completed · Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · study chair
- N/ANCT00242723 · Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung LiningNational Cancer Institute (NCI) · recruiting · Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS · principal investigator
- Ph1NCT00094978 · Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumNational Cancer Institute (NCI) · terminated · Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms · principal investigator
- Ph1NCT00020007 · Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By SurgeryNational Cancer Institute (NCI) · completed · Lung Cancer, Metastatic Cancer · study chair
- Ph1NCT00020124 · Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the LungsNational Institutes of Health Clinical Center (CC) · completed · Lung Cancer, Malignant Mesothelioma, Metastatic Cancer · study chair
- Ph1NCT00019825 · Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the PleuraNational Cancer Institute (NCI) · completed · Esophageal Cancer, Lung Cancer, Malignant Mesothelioma · study chair
- Ph1NCT00037817 · Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesNational Cancer Institute (NCI) · completed · Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Epigenetic Mechanisms of Gene Expression in Thoracic MalignanciesZIABC011115 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $870,353 awarded in 2025Same name and institution; not confirmed by an ID
- Epigenetic Therapy for Thoracic MalignanciesZIASC010093 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2025 · $1,305,530 awarded in 2025Same name and institution; not confirmed by an ID
- Modulating Cancer Stem Cell Signaling in Thoracic MalignanciesZIABC011418 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2011 to 2025 · $1,740,707 awarded in 2025Same name and institution; not confirmed by an ID
- Thoracic Surgery Consultative ServicesZIDBC011911 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $435,177 awarded in 2025Same name and institution; not confirmed by an ID
- Surgical Consultative Services in the Thoracic and Oncologic Surgery BranchZIDBC011541 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2018 · $3,025,821 awarded in 2018Same name and institution; not confirmed by an ID
- TOSB Surgical Oncology Fellowship ProgramZIEBC011542 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2018 · $1,588,556 awarded in 2018Same name and institution; not confirmed by an ID
- Epigenetic Alterations Induced by Tobacco SmokeZIABC011122 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2013 · $544,723 awarded in 2013Same name and institution; not confirmed by an ID
- Epigenetic Alterations Induced by Tobacco SmokeZ01BC011122 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $624,166 awarded in 2008Same name and institution; not confirmed by an ID
- Epigenetic Mechanisms of Gene Expression in Lung Cancer CellsZ01BC011115 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $520,139 awarded in 2008Same name and institution; not confirmed by an ID
- Targeting the Epigenome for Lung Cancer TherapyZ01SC010093 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $936,250 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:02 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.J Natl Cancer Inst · 1999392 citationsRCR 8.1
- Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.Ann Thorac Surg · 1997196 citationsRCR 7.5
- Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.Clin Cancer Res · 2006195 citationsRCR 3.7
- Clinical and molecular responses in lung cancer patients receiving Romidepsin.Clin Cancer Res · 2008110 citationsRCR 2.2
- Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.Semin Oncol · 1998100 citationsRCR 2.2
- A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.Clin Cancer Res · 201480 citationsRCR 2.3
- 53 citationsRCR 1.4
- Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).Cancer Gene Ther · 200046 citationsRCR 0.9
- Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.J Thorac Oncol · 201119 citationsRCR 0.5